Experimental drug ruxolitinib joins standard therapy in brain cancer battle

NCT ID NCT03514069

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested whether adding the experimental drug ruxolitinib to standard radiation and chemotherapy (temozolomide) is safe for people with newly diagnosed high-grade gliomas or glioblastoma. Ruxolitinib targets proteins that help cancer cells grow. The study enrolled 60 participants and focused on finding the best dose and monitoring side effects. It is a first step toward possibly improving treatment for these aggressive brain tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ruxolitinib
What this could lead to
If successful, this could point toward a new combination treatment for aggressive brain cancers like glioblastoma.
What could go wrong
This is an early Phase 1 safety and dosing study with only 60 participants. The drug may not improve outcomes or could cause side effects like low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.